1. Home /
    2. Altai Protocol Library /
  2. New Drug: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

New Drug: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Study:
  • International, open-label, phase 3 trial
  • Metastatic CRPC, previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens
  • 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone
Efficacy:
  • Imaging-based mPFS: 8.7 vs. 3.4 months [HR:0.40, 0.29-0.57; P<0.001]
  • mOS: 15.3 vs. 11.3 months; [HR, 0.62; 0.52-0.74; P<0.001]
Safety:
  • Grade >= 3 AEs: 52.7% vs 38.0%
  • All grades fatigue 43.1%, dry mouth 38.8%, nausea 35.3%, anemia 31.8% in the 177Lu-PSMA-617 group

N Engl J Med 2021 Sep 16;385(12):1091-1103.

Sartor, Oliver et al. “Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

https://doi.org/10.1056/nejmoa2107322

Reviewed by Hasan Çağrı Yıldırım, MD on May 30, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More